|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM279959478 |
| 003 |
DE-627 |
| 005 |
20231225024236.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201705581
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0933.xml
|
| 035 |
|
|
|a (DE-627)NLM279959478
|
| 035 |
|
|
|a (NLM)29333661
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lee, Eun Jung
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.03.2019
|
| 500 |
|
|
|a Date Revised 30.09.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a A growing appreciation of the relationship between the immune system and the tumorigenesis has led to the development of strategies aimed at "re-editing" the immune system to kill tumors. Here, a novel tactic is reported for overcoming the activation-energy threshold of the immunosuppressive tumor microenvironment and mediating the delivery and presentation of tumor neoantigens to the host's immune system. This nature-derived nanocage not only efficiently presents ligands that enhance cancer cell phagocytosis, but also delivers drugs that induce immunogenic cancer cell death. The designed nanocage-therapeutics induce the release of neoantigens and danger signals in dying tumor cells, and leads to enhancement of tumor cell phagocytosis and cross-priming of tumor specific T cells by neoantigen peptide-loaded antigen-presenting cells. Potent inhibition of tumor growth and complete eradication of tumors is observed through systemic tumor-specific T cell responses in tumor draining lymph nodes and the spleen and further, infiltration of CD8+ T cells into the tumor site. Remarkably, after removal of the primary tumor, all mice treated with this nanocage-therapeutics are protected against subsequent challenge with the same tumor cells, suggesting development of lasting, tumor-specific responses. This designed nanocage-therapeutics "awakens" the host's immune system and provokes a durable systemic immune response against cancer
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CD47 blockade
|
| 650 |
|
4 |
|a immunogenic cell death
|
| 650 |
|
4 |
|a intrinsic anticancer vaccination
|
| 650 |
|
4 |
|a nanocages
|
| 650 |
|
4 |
|a therapeutics
|
| 700 |
1 |
|
|a Nam, Gi-Hoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Na Kyeong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kih, Minwoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koh, Eunee
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Yoon Kyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hong, Yeonsun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Soyoun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Seung-Yoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jeong, Cherlhyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Yoosoo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, In-San
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 30(2018), 10 vom: 15. März
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:30
|g year:2018
|g number:10
|g day:15
|g month:03
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201705581
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 30
|j 2018
|e 10
|b 15
|c 03
|